No. The supplied human research does not show that taking MOTS-c causes weight loss. Human studies mainly measure MOTS-c levels during exercise or illness. A recruiting Phase 2 study is examining insulin sensitivity, but it has not reported weight-loss or safety results. 1 2 6
Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.
See if you qualify →What is MOTS-c?
MOTS-c is a mitochondrial-derived peptide. Mitochondria are structures inside cells that help make energy. Researchers are studying whether MOTS-c participates in metabolic signaling, meaning the cell signals involved in energy use and glucose handling. 5
That biology makes MOTS-c interesting for research. It does not show that a MOTS-c product changes body weight in people. A biological role, a blood-level measurement, and a tested treatment are three different questions. 5
Can MOTS-c help with weight loss?
No completed human weight-loss trial is included in the supplied research. The available studies assess circulating MOTS-c levels, not whether administered MOTS-c produces weight loss in people. 1 2 3 4
This matters because a change in a blood biomarker does not prove that giving that biomarker as a treatment will work. It also cannot establish what side effects, medication interactions, or long-term risks an administered peptide may have. 1 2 5
| Question | What the supplied evidence can answer | What it cannot answer |
|---|---|---|
| Does exercise affect circulating MOTS-c? | Human exercise studies measured changes in circulating MOTS-c. 1 2 | Whether taking MOTS-c leads to weight loss. |
| Do health conditions relate to measured MOTS-c levels? | Clinical studies have measured MOTS-c in breast cancer and cardiometabolic settings. 3 4 | Whether MOTS-c treatment improves those conditions. |
| Is MOTS-c being formally studied? | A recruiting Phase 2 study lists insulin sensitivity as its focus. 6 | Whether MOTS-c is effective or safe; no trial results are posted. |
What does human research on MOTS-c actually show?
Human research in the supplied set mostly asks whether circulating MOTS-c changes under certain conditions. Those are useful observational or exercise-related questions, but they are not treatment trials for weight loss. 1 2
Exercise studies measure MOTS-c rather than prescribe it
A 2021 human study reported that acute endurance exercise stimulated circulating mitochondrial-derived peptides, including MOTS-c. Another 2021 randomized exercise study examined MOTS-c in breast cancer survivors during aerobic and resistance exercise. Neither study tested administered MOTS-c as a weight-loss treatment. 1 2
Clinical studies show associations, not treatment effects
A 2022 paper measured circulating MOTS-c in people with breast cancer treated with metformin. A 2020 study examined mitochondrial-derived peptide-c in people with type 2 diabetes and coronary artery disease. These clinical contexts do not establish that MOTS-c administration causes weight loss or improves insulin sensitivity. 3 4
A newer study also measured MOTS-c during heat stress and calf-muscle immobilization in active men. Measuring a level during a stress or exercise condition is not the same as testing a MOTS-c treatment. 7
What do animal and cell findings mean for people trying to lose weight?
Animal and cell studies can help researchers form hypotheses about metabolism. They cannot establish a patient benefit, safe dose, or real-world side-effect profile in people. The 2023 review of MOTS-c research describes potential therapeutic interest while also reflecting a field that needs stronger human testing. 5
Be careful with claims that a peptide “increases metabolism” based on a lab pathway, a biomarker, or an animal result. For weight loss, the meaningful human outcome is a completed trial that reports changes in body weight and safety, not a promising mechanism alone. 5
Is MOTS-c being tested for insulin sensitivity or weight loss?
Yes, a recruiting Phase 2 study with 120 planned participants is listed for adults with prediabetes and overweight or obesity. Its stated focus is improving insulin sensitivity, not an established weight-loss result. 6
A trial listing tells you what researchers plan to study. It does not tell you that participants have benefited, that risks are known, or that the treatment is appropriate for any individual. 6
Other registered studies involving MOTS-c in the supplied sources concern measurement during renal transplantation or cardiovascular research. They add to the research landscape, but they do not provide evidence for MOTS-c as a weight-loss treatment. 8 9
What are the safety and product-quality questions around MOTS-c?
The most accurate answer is that completed human studies are needed to define the safety of administered MOTS-c for weight loss. The supplied studies do not provide that answer because they measure MOTS-c or study different clinical questions. 1 2 3 6
- Ask whether a claim comes from a completed human treatment trial or from a biomarker, animal, or cell study.
- Ask what outcomes were measured: body weight, insulin sensitivity, side effects, or only circulating peptide levels.
- Discuss prediabetes, other health conditions, and all medicines or supplements with a licensed clinician before considering an investigational peptide.
- Seek urgent medical care for severe or rapidly worsening symptoms after taking any substance.
Avoid relying on no-prescription research-chemical sellers for products intended for human use. A licensed clinician can help you weigh evidence, interactions, and safer next steps for your goals.
What evidence-based weight-loss options can I discuss with a clinician?
Weight management is more useful when it starts with your health history, eating pattern, activity, sleep, medicines, and conditions such as prediabetes. A clinician can help decide whether nutrition support, activity changes, treatment of a related condition, or prescription medication evaluation fits your situation.
MOTS-c is not the same as a GLP-1 receptor agonist. If you are sorting through peptide claims, our guides to weight-loss peptides, peptide injections for weight loss, and GLP-1 peptides explain the difference between established medication categories and early-stage peptide research.
For people with prediabetes, a clinician can also put weight concerns in the context of blood sugar, cardiovascular risk, current medicines, and personal goals. That is more informative than choosing a peptide based on a metabolism claim alone.
How can I evaluate online claims about peptides for weight loss?
Look first for a completed human trial that measured body weight and reported side effects. A recruiting study is not a result, even when its title sounds promising. 6
- 1Check whether the source studied administered MOTS-c in people, rather than only measuring MOTS-c in blood.
- 2Check whether the outcome was body weight, not only a laboratory marker or a proposed mechanism.
- 3Look for the study size, comparison group, time frame, and reported side effects.
- 4Separate peer-reviewed human findings from animal research, cell research, promotional copy, and social-media claims.
- 5Bring questions about peptide products and medication interactions to a licensed clinician.
For a deeper review of the evidence and research limits, see what MOTS-c is, MOTS-c peptide benefits, and what MOTS-c dosage research can and cannot tell us.
Frequently asked questions about MOTS-c and weight loss
No. MOTS-c is a mitochondrial-derived investigational peptide. GLP-1 receptor agonists are a separate medication class with different biology and clinical evidence. 5
A recruiting Phase 2 study is examining insulin sensitivity in adults with prediabetes and overweight or obesity, but it has not established safety or benefit. Discuss prediabetes and peptide questions with a licensed clinician. 6
References
- 1.von Walden F, Fernandez-Gonzalo R, Norrbom J, et al. Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans. Journal of Applied Physiology. 2021.
- 2.Dieli-Conwright CM, Sami N, Norris MK, et al. Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c in Hispanic and Non-Hispanic White breast cancer survivors. Scientific Reports. 2021.
- 3.Cuyàs E, Verdura S, Martin-Castillo B, et al. Circulating levels of MOTS-c in patients with breast cancer treated with metformin. Aging. 2022.
- 4.Ikonomidis I, Katogiannis K, Kyriakou E, et al. β-Amyloid and mitochondrial-derived peptide-c are additive predictors of adverse outcome to high-on-treatment platelet reactivity in type 2 diabetics with revascularized coronary artery disease. Journal of Thrombosis and Thrombolysis. 2020.
- 5.Zheng Y, Wei Z, Wang T. MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation. Frontiers in Endocrinology. 2023.
- 6.ClinicalTrials.gov. MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity (NCT07505745). 2026.
- 7.Elhusseiny R, Ihsan M, Labidi M, et al. Repeated Heat Stress Modulates the Levels of the Mitokines MOTS-C and FGF21 in Active Men during Calf Muscle Immobilization. Medicine and Science in Sports and Exercise. 2025.
- 8.ClinicalTrials.gov. Comparison of the Effects of General Anesthesia and Combined Spinal-Epidural Anesthesia on Ferroptosis, Humanin and MOTS-c Levels in Renal Transplantation (NCT07678073). 2026.
- 9.ClinicalTrials.gov. Platelet Reactivity, B-amyloid, MOTS-c and Mortality of Type II Diabetics With CAD (NCT04027712). 2026.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if GLP-1 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.


